A method for producing a radiopharmaceutical composition for positron emission tomography imaging of neurodegenerative diseases of the brain comprising: an effective amount of ( -4-(2-(6-(2-(2-(2-[ 18 F] fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); 10.0% (v/v) of ethyl alcohol; and 0.5 % (w/v) of sodium ascorbate, in 0.9% (w/v) aqueous sodium chloride, wherein the method comprises the steps of: preparing a mono Boc-protected vinylaniline compound; converting the vinylaniline compound to a methyl, t-butyl carbamate derivative; reacting 2-halo 5-iodopyridine with triethyleneglycol; reacting the methyl, t-butyl carbamate derivative with the resultant compound of the step of reacting 2-halo 5-iodopyridine with triethyleneglycol to produce -tert-Butyl 4-(2-(6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)phenyl(methyl)carbamate; and reacting the -tert-Butyl 4-(2-(6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)phenyl(methyl)carbamate with tosyl chloride to form -2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate; reacting -2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate and an -fluoride ion in dimethylsulfoxide (DMSO) solution or high-boiling point aprotic solvent to produce -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); isolating the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); purifying the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); and formulating the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamme) in an 0.9% (w/v) aqueous sodium chloride-ethyl alcohol solution comprising ethyl alcohol at 10.0% (v/v) of the total composition and sodium ascorbate at 0.5 % (w/v) of the total composition. an effective amount of ( -4-(2-(6-(2-(2-(2-[ 18 F] fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); 10.0% (v/v) of ethyl alcohol; and 0.5 % (w/v) of sodium ascorbate, in 0.9% (w/v) aqueous sodium chloride, wherein the method comprises the steps of: preparing a mono Boc-protected vinylaniline compound; converting the vinylaniline compound to a methyl, t-butyl carbamate derivative; reacting 2-halo 5-iodopyridine with triethyleneglycol; reacting the methyl, t-butyl carbamate derivative with the resultant compound of the step of reacting 2-halo 5-iodopyridine with triethyleneglycol to produce -tert-Butyl 4-(2-(6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)phenyl(methyl)carbamate; and reacting the -tert-Butyl 4-(2-(6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)phenyl(methyl)carbamate with tosyl chloride to form -2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate; reacting -2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate and an -fluoride ion in dimethylsulfoxide (DMSO) solution or high-boiling point aprotic solvent to produce -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); isolating the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); purifying the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); and formulating the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamme) in an 0.9% (w/v) aqueous sodium chloride-ethyl alcohol solution comprising ethyl alcohol at 10.0% (v/v) of the total composition and sodium ascorbate at 0.5 % (w/v) of the total composition. preparing a mono Boc-protected vinylaniline compound; converting the vinylaniline compound to a methyl, t-butyl carbamate derivative; reacting 2-halo 5-iodopyridine with triethyleneglycol; reacting the methyl, t-butyl carbamate derivative with the resultant compound of the step of reacting 2-halo 5-iodopyridine with triethyleneglycol to produce -tert-Butyl 4-(2-(6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)phenyl(methyl)carbamate; and reacting the -tert-Butyl 4-(2-(6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)phenyl(methyl)carbamate with tosyl chloride to form -2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate; reacting -2-(2-(2-(5-(4-(tert-butoxycarbonyl(methyl)amino)styryl)pyridin-2-yloxy)ethoxy)ethoxy)ethyl 4-methylbenzene sulfonate and an -fluoride ion in dimethylsulfoxide (DMSO) solution or high-boiling point aprotic solvent to produce -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); isolating the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); purifying the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine); and formulating the -4-(2-(6-(2-(2-(2-[ 18 F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamme) in an 0.9% (w/v) aqueous sodium chloride-ethyl alcohol solution comprising ethyl alcohol at 10.0% (v/v) of the total composition and sodium ascorbate at 0.5 % (w/v) of the total composition.